

HB 2305 -- PHARMACY SERVICES INSURANCE COVERAGE

SPONSOR: Wright

This bill establishes requirements for insurance coverage of certain pharmacy services. This bill provides that a health carrier, pharmacy benefits manager, or agent of such entities are prohibited from imposing any penalty, impediment, differentiation, or limitation on:

- (1) Participating providers for providing medically necessary clinician-administered drugs, regardless of whether the participating provider obtains such drugs from a provider that is in the network;
- (2) A person who is administered medically necessary clinician-administered drugs regardless of whether the participating provider obtains such drugs from a provider that is in the network; or
- (3) Any pharmacy, including any class B hospital pharmacy as defined in Section 338.220, RSMo, that is dispensing medically necessary clinician-administered drugs regardless of whether the participating provider obtains such drugs from a provider that is in the network.

This prohibition does not apply if the clinician-administered drug is not otherwise covered by the health carrier or pharmacy benefits manager.

A health carrier, pharmacy benefits manager, or agent of such entities may not discriminate, lower the reimbursement, or impose any separate contract terms upon an entity based upon that entity's participation in the 340B drug pricing program, described in 42 U.S.C. Section 256b, or limit a patient's freedom to use any such entity, as described in the bill.

All pharmacy claims processed by a pharmacy that participates in the 340B drug pricing program are final at the point of adjudication.

This bill defines "biological product", "biosimilar product", and "reference product" as having the same meaning as given to the terms under federal law. A health carrier, pharmacy benefits manager, or agent of such entities that provides coverage for a reference product or biosimilar biological product must provide coverage for the reference product and all biological products that have been deemed biosimilar to the reference product.